Olca Basturk1,2, Burcu Saka3, Serdar Balci4, Lauren M Postlewait5, Jessica Knight6, Michael Goodman6, David Kooby5, Juan M Sarmiento7, Bassel El-Rayes8, Hyejeong Choi4, Pelin Bagci4, Alyssa Krasinskas4, Brian Quigley4, Michelle D Reid4, Gizem Akkas4, Shishir K Maithel5, Volkan Adsay9. 1. Department of Pathology, New York University, New York, NY, USA. 2. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Pathology, Istanbul Medipol University, Istanbul, Turkey. 4. Department of Pathology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA. 5. Department of Surgical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA. 6. Department of Epidemiology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA. 7. Department of General Surgery, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA. 8. Department of Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA. 9. Department of Pathology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA. volkan.adsay@emory.edu.
Abstract
BACKGROUND: The current tumor-node-metastasis staging system for the pancreas does not incorporate the number of lymph nodes (LNs) with metastasis. METHODS: Among 1649 pancreaticoduodenectomies, 227 stringently defined pancreatic ductal adenocarcinomas (PDACs) that had undergone a specific approach of LN harvesting were analyzed for the prognostic value of LN substaging protocols used for other gastrointestinal (GI) organs. RESULTS: The median number of LNs harvested was 18, and the median number of LNs with metastasis was 3. Lymph node metastasis was detected in 175 cases (77 %). The number of LNs involved correlated significantly with clinical outcome. When cases were substaged with the protocol already in use for the upper GI organs (N0: no metastasis, N1: metastasis to 1-2 LNs; N2: metastasis to ≥3 LNs), the median overall survival times were 35, 21, and 18 months, and the respective 3-year survival rates were 46, 34, and 20 % (p = 0.004). Analysis of the Surveillance, Epidemiology and End Results (SEER) database also confirmed the survival differences between these substages (median overall survival times of 23, 15, and 14 months and respective 3-year survival rates of 37, 22, and 18 %; p < 0.0001). The substaging protocol for the lower GI organs (N0: no metastasis; N1: metastasis to 1-3 LNs; N2: metastasis to ≥4 LNs) also was significant, with median overall survival times of 35, 21, 18 months and respective 3-year survival rates of 46, 26, and 23 %; p = 0.009). The association between higher N stage and shorter survival persisted with multivariate modeling for both protocols, although the prognostic value of the upper GI protocol appeared to be slightly stronger according to the Akaike Information Criterion method. CONCLUSION: In conclusion, with proper LN harvesting, the LN metastasis rate in PDACs is very high (77 %). Substaging of LN metastasis has significant prognostic value and needs to be considered in the N staging of PDACs. The protocol already in use for other upper GI tract organs, which currently also is proven significant for ampulla, would be preferable, although the lower GI tract protocol also is applicable.
BACKGROUND: The current tumor-node-metastasis staging system for the pancreas does not incorporate the number of lymph nodes (LNs) with metastasis. METHODS: Among 1649 pancreaticoduodenectomies, 227 stringently defined pancreatic ductal adenocarcinomas (PDACs) that had undergone a specific approach of LN harvesting were analyzed for the prognostic value of LN substaging protocols used for other gastrointestinal (GI) organs. RESULTS: The median number of LNs harvested was 18, and the median number of LNs with metastasis was 3. Lymph node metastasis was detected in 175 cases (77 %). The number of LNs involved correlated significantly with clinical outcome. When cases were substaged with the protocol already in use for the upper GI organs (N0: no metastasis, N1: metastasis to 1-2 LNs; N2: metastasis to ≥3 LNs), the median overall survival times were 35, 21, and 18 months, and the respective 3-year survival rates were 46, 34, and 20 % (p = 0.004). Analysis of the Surveillance, Epidemiology and End Results (SEER) database also confirmed the survival differences between these substages (median overall survival times of 23, 15, and 14 months and respective 3-year survival rates of 37, 22, and 18 %; p < 0.0001). The substaging protocol for the lower GI organs (N0: no metastasis; N1: metastasis to 1-3 LNs; N2: metastasis to ≥4 LNs) also was significant, with median overall survival times of 35, 21, 18 months and respective 3-year survival rates of 46, 26, and 23 %; p = 0.009). The association between higher N stage and shorter survival persisted with multivariate modeling for both protocols, although the prognostic value of the upper GI protocol appeared to be slightly stronger according to the Akaike Information Criterion method. CONCLUSION: In conclusion, with proper LN harvesting, the LN metastasis rate in PDACs is very high (77 %). Substaging of LN metastasis has significant prognostic value and needs to be considered in the N staging of PDACs. The protocol already in use for other upper GI tract organs, which currently also is proven significant for ampulla, would be preferable, although the lower GI tract protocol also is applicable.
Authors: Peter J Allen; Deborah Kuk; Carlos Fernandez-Del Castillo; Olca Basturk; Christopher L Wolfgang; John L Cameron; Keith D Lillemoe; Cristina R Ferrone; Vicente Morales-Oyarvide; Jin He; Matthew J Weiss; Ralph H Hruban; Mithat Gönen; David S Klimstra; Mari Mino-Kenudson Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: Chad A Barnes; Ashley N Krepline; Mohammed Aldakkak; Callisia N Clarke; Kathleen K Christians; Abdul H Khan; Bryan C Hunt; Paul S Ritch; Ben George; William A Hall; Beth A Erickson; Douglas B Evans; Susan Tsai Journal: J Gastrointest Surg Date: 2017-08-28 Impact factor: 3.452
Authors: Douglas S Swords; Matthew A Firpo; Kirsten M Johnson; Kenneth M Boucher; Courtney L Scaife; Sean J Mulvihill Journal: Surgery Date: 2017-02-21 Impact factor: 3.982
Authors: Vicente Morales-Oyarvide; Douglas A Rubinson; Richard F Dunne; Margaret M Kozak; Justin L Bui; Chen Yuan; Zhi Rong Qian; Ana Babic; Annacarolina Da Silva; Jonathan A Nowak; Natalia Khalaf; Lauren K Brais; Marisa W Welch; Caitlin L Zellers; Kimmie Ng; Daniel T Chang; Rebecca A Miksad; Andrea J Bullock; Jennifer F Tseng; Richard S Swanson; Thomas E Clancy; David C Linehan; Jennifer J Findeis-Hosey; Leona A Doyle; Jason L Hornick; Shuji Ogino; Charles S Fuchs; Aram F Hezel; Albert C Koong; Brian M Wolpin Journal: Br J Cancer Date: 2017-10-05 Impact factor: 7.640